Athersys (ATHX) Provides MultiStem Clinical Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. SPY
2. PCVX
3. NVDA
4. KLC
5. TSLA
6. PTC
7. CME
8. USO
9. AMD
10. EVTL

Go back to Athersys (ATHX) Provides MultiStem Clinical Update

Athersys Provides MultiStem Clinical Update

January 9, 2023 8:30 AM EST

Enrollment completed in second cohort of MATRICS-1 trial in hemorrhagic trauma
Enrollment reaches halfway mark in MASTERS-2 trial in ischemic stroke

CLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2). MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory... More